Open Access Publishing
Publishing open access in this journal
The Pharmacogenomics Journal is a Transformative Journal (TJ). When research is accepted for publication, authors can choose to publish using either the traditional publishing route OR via immediate gold Open Access.
The Pharmacogenomics Journal is actively committed to becoming a fully Open Access journal. We will increase the number of articles we publish OA, with the eventual goal of becoming a fully Open Access journal. A journal that commits to this process is known as a Transformative Journal.
Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route, the journal's standard licensing terms will need to be accepted, including self-archiving policies. Those licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.
Benefits of open access
Publishing OA offers a number of benefits, including greater reach and readership for your work:
Find out more about benefits of OA.
Fees and funding
To publish OA in The Pharmacogenomics Journal, authors are required to pay an article processing charge (APC). The APC is determined at the date of acceptance. The APC for all published articles is as follows, subject to VAT or local taxes where applicable:
Visit our OA support portal for further information. Authors can also choose to publish under the traditional publishing model (no APC charges apply); both options will be offered after the paper has been accepted.
Open access funding
Visit the Springer Nature OA funding and support service for information about research funders and institutions that provide funding for APCs.
Springer Nature offers agreements that enable institutions to cover OA publishing costs. Learn more about our OA agreements to check your eligibility and discover whether this journal is included.
Creative Commons licenses
OA articles in Springer Nature journals are published under Creative Commons licenses. These provide an industry-standard framework to support easy re-use of OA material. Under Creative Commons licenses, authors retain copyright of their articles.
The Pharmacogenomics Journal articles are published OA under a CC BY license (Creative Commons Attribution 4.0 International license). The CC BY license is the most open license available, and is considered the industry 'gold standard' for open access; it is also preferred by many funders. This license allows readers to copy and redistribute the material in any medium or format, and to alter, transform, or build upon the material, including for commercial use, providing the original author is credited.
In instances where authors are not allowed to retain copyright to their own article (where the author is a US Government employee for example), authors should contact the Open Research Support team (ORSupport@springernature.com) before submitting their article so we can advise as to whether their non-standard copyright request can be accommodated.
Authors are advised to check their funder's requirements before selecting OA, to ensure compliance. Learn more about funder compliance.